Company Filing History:
Years Active: 2023
Title: The Innovative Contributions of Pamela Weinstein
Introduction
Pamela Weinstein is a notable inventor based in Cambridge, MA (US). She has made significant strides in the field of cancer treatment through her innovative work. With a focus on developing advanced therapeutic solutions, her contributions are paving the way for new approaches in oncology.
Latest Patents
Pamela Weinstein holds a patent for the Twin Immune Cell Engager (TWICE). This invention is a kit or composition designed for treating cancer, comprising a first component and a second component. Each component includes a targeting moiety that binds to a tumor antigen expressed by the cancer or an antigen expressed by a non-cancer cell in the tumor microenvironment. The first and second components each contain an immune cell binding domain capable of immune cell binding activity when interacting with the immune cell binding domain in the other component. Additionally, they may include a complementary binding domain that binds to a complementary antigen when interacting with the complementary binding domain in the other component. In some embodiments, the components may also feature a complementary functional domain with activity when targeted to the cancer cell or its microenvironment. This patent represents a significant advancement in cancer therapy.
Career Highlights
Pamela Weinstein has established herself as a key figure in the field of biomedical innovation. Her work at Revitope Limited has allowed her to focus on developing cutting-edge solutions for cancer treatment. With her expertise and dedication, she continues to contribute to the advancement of medical technology.
Collaborations
Throughout her career, Pamela has collaborated with talented individuals such as Martin Preyer and Allison Colthart. These partnerships have fostered an environment of innovation and creativity, leading to the development of impactful solutions in the medical field.
Conclusion
Pamela Weinstein's contributions to cancer treatment through her patent for the Twin Immune Cell Engager exemplify her commitment to advancing medical science. Her work not only highlights her innovative spirit but also underscores the importance of collaboration in achieving groundbreaking results.